Form 4: Skye Bioscience Director Granted 35,000 Stock Options

Skye Bioscience Director Karen L. Smith was granted 35,000 stock options with an exercise price of $0.82, vesting over one year.

Summary

• Karen L. Smith, a Director of Skye Bioscience, Inc. (SKYE), was granted 35,000 stock options.
• The transaction date for the option grant was February 6, 2026.
• Each stock option has an exercise price of $0.82.
• The options vest in equal monthly installments over a one-year period, commencing on January 19, 2026.
• The expiration date for these stock options is February 6, 2036.
• Following this transaction, Karen L. Smith beneficially owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine director compensation and aligns the director's interests with long-term shareholder value, without indicating any significant operational or financial changes.

Positives

• The grant of stock options to Director Karen L. Smith aligns her financial interests with those of common shareholders, potentially incentivizing long-term value creation.

Future Outlook

The granted stock options will vest in equal monthly installments over a one-year period starting January 19, 2026, indicating a future schedule for the director's equity accumulation.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of compensation designed to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• Option grants are a common component of executive and director compensation packages across various industries, including biotechnology, to attract and retain talent and align interests.
• The vesting schedule over one year is a relatively short period compared to typical multi-year vesting schedules (e.g., 3-4 years) often seen for executive stock options, which might suggest a focus on near-term performance or a specific retention strategy for directors.

Related Party Transactions

• Skye Bioscience, Inc. granted 35,000 stock options to Karen L. Smith, a Director of the company, at an exercise price of $0.82.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: This filing does not directly impact general employees, as it pertains to director compensation.

Next Steps

• The stock options will vest in equal monthly installments over the one-year period beginning January 19, 2026.

Key Dates

Keywords

Skye Bioscience, SKYE, Stock Options, Insider Transaction, Director Compensation, Form 4, Equity Grant